Prof Dr Arnulf Stenzl, Universität Tübingen, Tübingen Deutschland ,Germany
Prof. Dr. Arnulf Stenzl is an Austrian-born urologist and global leader in urological oncology. He received his medical degree from Karl-Franzens University in Graz, Austria, in 1980 and subsequently trained in surgery and urology across Austria, Switzerland, and the United States. Since 2002, he has headed the Department of Urology at Eberhard-Karls University in Tübingen, Germany, where he oversees critical research on urological cancers. Prof. Stenzl’s contributions extend internationally, with membership in numerous editorial boards and global collaborations. He has played a pivotal role in shaping European urological policies as Secretary General of the European Association of Urology. His work has led to several groundbreaking patents in the field, furthering innovations in patient care.
Professional Profile
Education
Prof. Dr. Arnulf Stenzl embarked on his academic journey in 1973 when he enrolled at Karl-Franzens University in Graz, Austria, where he earned his Doctor medicinae universalis (M.D.) in February 1980. His initial training spanned internal medicine, nephrology, and pathology at Landeskrankenhaus Klagenfurt and Karl-Franzens University. From 1984 to 1987, he undertook specialized training in urology, first at Karl-Franzens University, then further expanding his knowledge as a fellow in general urology and urologic oncology at the University of California, Los Angeles (UCLA). His education, which encompassed diverse fields such as trauma, vascular, and plastic surgery, provided him with a holistic understanding of medicine and surgery. His dedication to learning has been reflected in his ongoing research and innovative contributions to urology.
Experience
Prof. Dr. Arnulf Stenzl has had a distinguished career spanning over three decades. After serving as an assistant professor at the University of Bern in Switzerland, he moved to the University of Innsbruck, Austria, where he eventually became vice-chairman of the Department of Urology. Since 2002, he has led the Department of Urology at Eberhard-Karls University Tübingen, Germany, overseeing the clinical, academic, and research arms of the institution. Prof. Stenzl has driven numerous groundbreaking research projects, collaborating with both academic and industrial partners. As Secretary General of the European Association of Urology, he has led European urological research and development initiatives. His expertise extends to cancer research, with numerous contributions to advancing treatment modalities for bladder and prostate cancer.
Awards and Honors
Prof. Dr. Arnulf Stenzl’s career is marked by numerous prestigious awards and honors. He is an honorary member of several international urological societies, including the Bristol Urological Institute and the Canadian Urological Association. His service as President of the German Urological Association (2020-2021) highlights his leadership within the field. Additionally, his involvement as Chairman of the Scientific Congress Office for the European Association of Urology and his role on the Board of Directors of the European CanCer Organisation demonstrate his commitment to global urological advancement. Prof. Stenzl’s contributions to scientific literature have earned him multiple editorial board memberships. His innovative spirit is further evidenced by several patents, including implantable devices to treat urinary incontinence and risk prediction models for renal cell carcinoma.
Research Focus
Prof. Dr. Arnulf Stenzl’s research is at the forefront of urological oncology, focusing on advanced treatment modalities for bladder and prostate cancers. His work delves into personalized cancer therapies, optimizing clinical outcomes through precision medicine approaches. A significant aspect of his research revolves around biomarker discovery and risk stratification, which aim to enhance early diagnosis and targeted treatment. He has contributed to pioneering studies in immunotherapy, including innovative techniques for bladder cancer surgery and the integration of novel hormonal therapies in prostate cancer treatment. Prof. Stenzl is also involved in collaborative research projects with industry, furthering the development of next-generation urological treatments. His innovative contributions have resulted in several patents, solidifying his standing as a leader in urological research and technology.
Publications top notes
- Treatment Intensification With Novel Hormonal Therapy in Prostate Cancer 📚🧪
- Sacituzumab Govitecan Efficacy in Urothelial Cancer 🧬🔬
- Co-occurring BRCA2/SPOP Mutations and PARP Inhibitor Sensitivity 🧬⚕️
- Epacadostat Plus Pembrolizumab for Urothelial Carcinoma 💉🧪
- Impact of Teratoma on Survival in Germ Cell Cancer 🧫🩺
- Sacituzumab Govitecan & Pembrolizumab in Urothelial Cancer 💊🧪
- TROPHY-U-01 Study on Sacituzumab Govitecan in Metastatic Urothelial Cancer 🧬🔬
- Efficacy of Darolutamide in Black Patients With Prostate Cancer ⚕️🩺
- Alpha Emitter for Metastatic Castration-Resistant Prostate Cancer 🧬💉